Status:
COMPLETED
Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum
Lead Sponsor:
Poitiers University Hospital
Conditions:
Atopic Dermatitis
Staphylococcus Aureus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Clinical studies have demonstrated a link between staphylococcal skin colonization and the pathogenesis of AD, but the impl...
Eligibility Criteria
Inclusion
- Patients with moderate AD (SCORAD between 25 and 50) or severe AD (SCORAD\> 50)
- Skin lesions in the forearms
- Free subject, without neither guardianship, wardship nor subordination
- Patient with Social Security
- Informed and signed consent by the patient after clear and loyal information on the study
Exclusion
- Age \< 18 year-old
- Patients with mild AD (SCORAD \< 25)
- Patients without skin lesions in the forearms
- Patients treated with dermocorticoid or calcineurin inhibitor for less than two weeks
- Patients under systemic treatment : Methotrexate, Ciclosporin, Mycophenolate Mofetil, Azathioprine, general corticosteroids for less than 4 weeks
- Patients under biological treatment : Dupilumab for less than 5 half-lives
- Patient without Social Security
- Pregnant and nursing women
Key Trial Info
Start Date :
October 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2025
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT04274348
Start Date
October 15 2020
End Date
August 4 2025
Last Update
December 29 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux
Bordeaux, France
2
CHU de Poitiers
Poitiers, France